Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.

Marianna Alunni-FabbroniKerstin RönschThomas HuberClemens C CyranMax SeidenstickerJulia MayerleMaciej PechBristi BasuChris VerslypeJulia BenckertPeter MalfertheinerJens Ricke

Published in: Journal of translational medicine (2019)

Taken together, the results support the prognostic value of cfDNA/ctDNA in advanced HCC patients with the potential to predict therapy response. These findings support the clinical utility of liquid biopsy in advanced HCC improving individualized therapy and possible earlier identification of treatment responders.

Keyphrases

circulating tumor
clinical trial
study protocol
randomized controlled trial
phase iii
single molecule
ionic liquid
stem cells
phase ii
cell free
risk assessment
combination therapy
open label
human health
cell therapy
nucleic acid
bioinformatics analysis